Valion Bio, Inc.

VBIO Healthcare Biotechnology

Valion Bio, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $780,000.00, down 33.7% from fiscal 2023.

Revenue
+15.9%
EPS
+0.91%
Free cash flow
−189.0%

Quarter to June 2026, against a year earlier

0.51 0.01 +2.00%
Market cap
$1.1M
P/E
0.0×
Fwd P/E
0.0×
Dividend yield
—
F-score
3/9
Altman Z
−21.96
Beneish M
48.80
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
— — — 3

+8 more TTM periods

ROE
(489.30%) (198.48%) (93.69%) (178.21%)
ROA
(104.96%) (66.64%) (52.63%) (156.02%)
ROIC
(61.01%) (41.17%) (26.95%) (152.85%)
Return on Tangible Assets
(153.07%) (74.89%) (36.22%) (241.07%)
Average Days of Receivables
— — — 14.39
Free Cash Flow per Share
(108.54) (96.84) (102.39) (115.34)
Free Cash Flow
(14.67) (11.17) (7.58) (6.09)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026